Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF

被引：0
|
作者：
Orkin, C. [1 ]
Antinori, A. [2 ]
Rockstroh, J. [3 ]
Guillen, S. Moreno [4 ]
Martorell, C. [5 ]
Molina, J. [6 ]
Lazzarin, A. [7 ]
Maggiolo, F. [8 ]
Yazdanpanah, Y. [9 ]
Andreatta, K. [10 ]
Huang, H. [11 ]
Hindman, J. [12 ]
Martin, H. [12 ]
Baeten, J. [12 ]
Pozniak, A. [13 ]
机构：
[1] Queen Mary Univ London, HIV Med, London, England
[2] Natl Inst Infect Dis, Lazzaro Spallanzani IRCCS, Rome, Italy
[3] Univ Hosp Bonn, Med Klin & Poliklin I, Bonn, Germany
[4] Hosp Ramon & Cajal, Dept Infect Dis, Madrid, Spain
[5] Res Inst, Infect Dis, Springfield, MA USA
[6] Univ Paris, Infect Dis, Paris, France
[7] San Raffaele Hosp Milan, Lazzaro Spallanzani IRCCS, Milan, Italy
[8] Azienda Osped Papa Giovanni XXIII, Infect Dis, Bergamo, Italy
[9] AP HP Hop Bichat, Infect Dis, Paris, France
[10] Gilead Sci, Clin Virol, Foster City, CA USA
[11] Gilead Sci, Biostat Virol, Foster City, CA USA
[12] Gilead Sci, Clin Dev, Foster City, CA USA
[13] Chelsea & Westminster Hosp, Clin Res, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P088
引用
收藏
页码：88 / 89
页数：2
相关论文
共 45 条
  • [41] Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48-144) of the BE RADIANT Phase 3b Trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Merola, Joseph F.
    Paul, Carle
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2841 - 2844
  • [42] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
    Maggiolo, F.
    Rizzardini, G.
    Raffi, F.
    Pulido, F.
    Mateo Garcia, G.
    Molina, J.
    Ong, E.
    Shao, Y.
    Corales, R.
    McNicholl, I.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [43] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Valero, I. Perez
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J. -M.
    Esser, S.
    McNicholl, I.
    Lorgeoux, R. -P.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 6 - 7
  • [44] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
    Perez-Valero, I.
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J-M
    Esser, S.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    McNicholl, I.
    Haubrich, R.
    HIV MEDICINE, 2019, 20 : 170 - 171
  • [45] A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Perez-Valero, I.
    Llibre, J. M.
    Pulido, F.
    Molina, J-M
    Esser, S.
    McNicholl, I.
    Lorgeoux, R-P
    Piontkowsky, D.
    Sathia, L.
    Haubrich, R.
    HIV MEDICINE, 2018, 19 : S21 - S21
12345